Catherine Holliday (Switzerland), 2019-22
Catherine (Kate) Holliday is Chief Executive of the Centre for Community-Driven Research (CCDR), a non- profit organisation driving a more person-centred health sector. Catherine’s professional work has focused on developing solutions to health system challenges and she has been actively involved in developing more equitable and systematic approaches to community engagement in HTA and all parts of the health system. At CCDR, she is leading the development of a global repository of patient experience data, global patient organisation networks, and piloting various ways for patients to better engage in decision-making and increase their access to treatments and services. She currently serves as a Board Director at Health Technology Assessment International (HTAi) and continues to work as a TeleHealth nurse.
She has significant experience working with government, industry, not- for-profit organisations as well as research and international organisations including working in Geneva, Switzerland with the Australian Department of Foreign Affairs and Trade, the International Organisation for Migration, and the GAVI Alliance. She has also worked as a nurse and researcher in Australia and the USA with roles including Head of Research at Cancer Council NSW Australia and Head of Policy and Strategy at the Kinghorn Cancer Centre (Sydney, Australia).
Her education includes a Bachelor of Nursing degree, a graduate diploma in nutrition, a Masters in Health Promotion, a Masters in Health Science and her PhD thesis investigated the relationship between the global, social and economic drivers of research and how to translate results into policy, practice and population health.
Wim Goettsch (Netherlands), 2019-22
Wim Goettsch, PhD is currently Special Advisor HTA at the Dutch National Health Care Institute. He was the Director of the EUnetHTA JA3 (2016-2020) Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. Since 2019, he has held a position as an Associate Professor at Utrecht University (NL), where he is leading a new H2020 consortium called HTx, New Methods for Health Technology Assessment (2019-2024) with fifteen partners around Europe. Between 2010 and 2015, he was the Project Leader of Work Package 5 of EUnetHTA Joint Action 1 & 2, in which rapid joint assessments of relative effectiveness of pharmaceuticals were piloted between more than 25 HTA organisations around Europe. Between 2010 and 2013, he was the Deputy Secretary of the Medicinal Products Reimbursement Committee at Dutch National Health Care Institute. He is currently a member of the HTAi Policy Forum Committee and has been Director in the Board (2013-2015) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Before joining the National Health Care Institute, he worked as a research manager for the PHARMO Institute and was responsible for the coordination of numerous pharmacoepidemiological and outcomes studies for international offices of pharmaceutical companies such as AstraZeneca, Novartis, Pfizer and GSK. He also worked as a senior epidemiologist in the field of antimicrobial resistance for the National Institute for Public Health and the Environment in the Netherlands and was involved in the initiation of the European Antimicrobial Resistance Surveillance Network (EARS-Net) that is now coordinated by the ECDC. He was also seconded as a scientific secretary for Dutch National Health Council on the topic of antimicrobial growth promotors in animal feed (1997-1998). He has a PhD in immunology and an advanced education in pharmaco- epidemiology and pharmaco-economics. He has more than 70 publications in peer-reviewed international journals.
Li Ying (Grace) Huang (Taiwan), 2020-23
Grace is a director and researcher at the Division of the Health Technology Assessment, Center for Drug Evaluation, Taiwan (CDE/HTA). Before joining CDE/HTA in 2008, Grace worked for 10 years as a clinical pharmacist in a leadership role in department of pharmacy in one of the major medical centers in Taipei. She completed her Ph.D. degree in Graduate Institute of Health Policy and Management, College of Public Health, National Taiwan University and Master’s degree in pharmaceutical science from the National Taiwan University as well. Grace has authored and co-authored articles published in Health Policy, The Journal of Clinical Pharmacology, Journal of Nephrology, European Review for Medical and Pharmacological Sciences, and many others. She also serves as a reviewer of manuscripts for several international journals. Her current research focuses on comparative efficacy of new drugs, applying mixed treatment comparison methods, patient involved HTA and therapeutic inertia among adult DM patients in Taiwan.
Grace is honored to serve as the board of director at INAHTA from 2016 to 2018 and 2019 to present. Grace was also invited as a panelist in HTAi workshop to share the experience of patient involvement in HTA at Taiwan and gain feedback from others.
Franz Waibel (Switzerland), 2020-23
Franz Waibel has over 30 years of experience in the field of value assessment of medicines and medical products and has been involved in matters related to HTA throughout his career. He has worked in a broad range of positions spanning several fields from science and research to managerial business roles, to roles in public affairs and policy as well as to advisory and consulting roles.
Since 2014, he provides services as an independent strategic advisor and consultant on issues related to Patient Access to medicines and medical products, Value Assessment and Value Communication, Health Technology Assessment and Health Policy. He has in addition a keen interest to share and apply his senior leadership experience. He provides trainings on leadership and team development, acts as coach, mentor and mediator and advises on organizational development and change management. He is passionate about strengthening patient involvement in HTA and in Healthcare, and he is also keen to further multi-stakeholder dialogues between the public sector, industry and with involvement of patients and citizens.
He has gained substantial leadership and business management experience through his 25 years corporate career. He has a strong track record in establishing organizational efficiency and effectiveness, leading through transformational change, implementing governance processes and developing young talents. He has led patient access, HTA, HEOR and Public Affairs functions with global, regional and local responsibilities within several corporations including Novartis, Pfizer, Merck&Co, Bayer and Vifor Pharma.
Franz is supporting HTAi and is involved in the society since 2005. He has been serving for a number of years on the HTAi Global Policy Forum. He is an active member of the HTAi Patient and Citizen Involvement IG and has been a member of the HTAi Regulatory Interactions and Conditional Coverage IG. Through his corporate roles he supported and encouraged numerous contributions to HTAi in the form of abstracts, publications, panels and symposia.
He lived and worked in Germany, Belgium, the USA and in Switzerland and has been engaged in healthcare system and HTA policy matters across many jurisdictions in Latin America, North America, Asia and Europe. He has been part of cross stakeholder initiatives at the EU level, he has been engaged in policy discussions across the globe and served on various association working groups, think tanks (e.g. CIRS) and boards (EuropaBio).
Franz studied Cell Biology, Genetics, and Pharmacology and graduated in human genetics at the University of Freiburg, Germany. He holds a PhD in Cell Biology from the University of Basel, Switzerland, and an MBA from the University of Birmingham, UK. In addition, he has completed post-graduate educations in Health Economics and Outcomes Research, various leadership trainings and he is a certified coach and mediator. Franz holds Swiss and German citizenships and lives with his wife in the Basel area in Switzerland.
Debjani (Jani) Mueller (South Africa), 2019-22
Debjani (Jani) Mueller, MEng is a Senior Researcher at Charlotte Maxeke Medical Research Cluster (CMeRC) in Johannesburg. She currently holds a faculty position with University of Pretoria in South Africa and is a doctoral candidate at the Technical University of Berlin.
Over the last decade, she has gained practical experience in evaluating medical devices as part of her work with the CMeRC team and shared her experience through training throughout South Africa and other parts of the world through distance-based education. She has taught hospital managers in South Africa (MPH in Hospital management) as an initiative of the EU and South African Department of Health.
Her research focuses on advancing the methods used in the area of medical device assessment to enhance its usefulness in the context of real-world decision-making which involves taking a life-cycle approach to medical technology assessment.
Jani continues to focus her effort on promotion, collaboration and raising awareness of sustainable HTA development and implementation. She was a founding member of South African HTA Society (SAHTAS), has been a director on the INAHTA Board since 2013, and is currently the chair of the HTAi Interest Group on developing Countries. She has served on the International Scientific Program Committee of HTAi’s Annual Meeting over the years and more recently is an Associate Editor of IJTAHC. Furthermore, she has been co-opted as a Board member by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) South Africa Chapter Board for the term 2018-2019.
Jani nurtures a keen interest in building competencies and education and training in HTA, especially in emerging settings. She has published and co-authored a number of articles, contributed to book chapters and presented her research findings to an array of scientific audiences.
Leonor Varela-Lema (Spain), 2019-22
Leonor Varela-Lema is BSc, PhD in Pharmacy and holds a Master’s Degree in Preventive Medicine and Public Health from the University of Santiago de Compostela (Spain). She has a 16 years background in health technology assessment and health care research, with recognized experience at the national and international level. Currently, she is the International Project Manager of the Health Technology Assessment Department (avalia-t) of the Galician Agency for Health Knowledge Management (ACIS).
During her career, she has coordinated important initiatives in the field of HTA, including the development of the Spanish NHS guideline that establishes the structured methodological framework for the implementation of post-introduction observational studies to support decision making and the development of the topic prioritisation and selection strategy. She has been involved in EUnetHTA since its inception (EUnetHTA Project (2006-2008), participating in the development of the first version of the “Core-Model” and other key documents, like the position paper on how to best formulate research recommendations for primary research arising from HTA. In the ongoing Joint Action 3 (2016-2020), she is leading two activity centre departments, which focus on HTA Joint Production and generation of cross border post-launch evidence for medical devices. She has participated in the EU funded SEED Consortium (Shaping Early Dialogues for Health Technologies) (2014-2015) and is currently part of non-pharma EUnetHTA early dialogues Working Group.
She has been an active member of HTAi since 2005. She has been a member of the Interest Groups on HTAi Disinvestment & Early Awareness and Regulatory interactions & Conditional coverage, and is a member of the HTA glossary Steering Committee, which supports the development of the HTA glossary, which is a collaboration of INAHTA and HTAi.
Leonor Varela-Lema has lectured extensively on HTA and has published more than 100 papers concerning related topics. She is as an evaluator of projects funded by the Funds for Health Research of the Spanish Ministry of Health and the Regional Government of Andalucía. Her main areas of expertise are: epidemiology, public health, HTA, health care service research and reimbursement policy making of medical devices and other non pharma technologies.
Vania Canuto (Brazil), 2020-23
Vania is an Economist with degrees in Pharmacoeconomics and Health Economics at Pompeu Fabra University of Barcelona and a master’s degree in Health Technology Assessment at ENSP/FIOCRUZ.
Since 2001, Vania has worked as a civil servant of the Ministry of the Economy – Brazil of the career of Specialist in Policies and Governmental Management. During the period of 2002-2009, Vania acted as Deputy Manager of New Medicines Price Evaluation at the Drug Market Regulation Chamber (CMED), at the Brazilian Health Regulatory Agency (Anvisa).
Vania has been working at the Ministry of Health since 2009 and she was Coordinator of Monitoring and Health Technology Assessment and Deputy Director of Department of Management and Incorporation of Technologies in Health from 2011 to 2017.
Since February 2018, Vania was given the opportunity to contribute as Deputy Secretary of the Secretariat of Science, Technology and Inputs, and in November 2018, she returned to the Department of Management and Incorporation of Technologies in Health and the National Committee for Health Technology Incorporation (CONITEC), as its Director.
Vania’s engagement at HTAi since 2006 allowed her to establish powerful exchanges with the most consolidated HTA agencies from other countries. As director of HTAi, Vania believes that she will be able to increase the dialogue between the different actors involved in HTA and its use in Latin America, as well as to encourage the creation of new ways of articulating these different perspectives for the common good.
Past President Sean Tunis (United States), 2019-21
Sean Tunis, MD, MSc, is the Founder, President and Chief Executive Officer of the Center for Medical Technology Policy (CMTP) in Baltimore, Maryland. CMTP is an independent, non-profit organization that provides a neutral platform for multi-stakeholder collaborations that are focused on improving the quality, relevance and efficiency of clinical research. His work currently focuses on expanding infrastructure for the conduct of pragmatic clinical trials within the health care delivery systems, developing condition-specific evidentiary standards for reimbursement, and promoting greater engagement of patients and consumers in clinical research. Tunis serves on the Board of HTAi, the Health Sciences Policy Council for ISPOR and a number of other advisory boards for public and private sector organizations focused on issues of comparative effectiveness, innovation, health technology assessment, evidence-based medicine, clinical research and reimbursement.